Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types.

Journal: Frontiers in genetics
Published Date:

Abstract

In the last four years, advances in Deep Learning technology have enabled the inference of selected mutational alterations directly from routine histopathology slides. In particular, recent studies have shown that genetic changes in clinically relevant driver genes are reflected in the histological phenotype of solid tumors and can be inferred by analysing routine Haematoxylin and Eosin (H&E) stained tissue sections with Deep Learning. However, these studies mostly focused on selected individual genes in selected tumor types. In addition, genetic changes in solid tumors primarily act by changing signaling pathways that regulate cell behaviour. In this study, we hypothesized that Deep Learning networks can be trained to directly predict alterations of genes and pathways across a spectrum of solid tumors. We manually outlined tumor tissue in H&E-stained tissue sections from 7,829 patients with 23 different tumor types from The Cancer Genome Atlas. We then trained convolutional neural networks in an end-to-end way to detect alterations in the most clinically relevant pathways or genes, directly from histology images. Using this automatic approach, we found that alterations in 12 out of 14 clinically relevant pathways and numerous single gene alterations appear to be detectable in tissue sections, many of which have not been reported before. Interestingly, we show that the prediction performance for single gene alterations is better than that for pathway alterations. Collectively, these data demonstrate the predictability of genetic alterations directly from routine cancer histology images and show that individual genes leave a stronger morphological signature than genetic pathways.

Authors

  • Chiara Maria Lavinia Loeffler
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Nadine T Gaisa
    Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.
  • Hannah Sophie Muti
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Marko van Treeck
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Amelie Echle
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Narmin Ghaffari Laleh
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Christian Trautwein
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Lara R Heij
    Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.
  • Heike I Grabsch
    Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center+, Maastricht, Netherlands.
  • Nadina Ortiz Bruechle
    Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany.
  • Jakob Nikolas Kather
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.

Keywords

No keywords available for this article.